---
schema_version: "secwatch.filing_event.v1"
accession: "0001818382-23-000014"
form_type: "8-K"
ticker: "HUMA"
cik: "0001818382"
company_name: "Humacyte, Inc."
filed_at: "2023-03-24T23:59:59+00:00"
generated_at: "2026-06-17T16:59:51.604816+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Humacyte nears enrollment completion in two pivotal HAV trials; cash to fund ops thru 2024

## Summary
- Phase 2/3 V005 trauma trial: 46 of 50 primary endpoint patients enrolled; BLA filing ~4 months after trial ends.
- Phase 3 V007 AV access trial: 238 of 240 patients enrolled; topline results one year after enrollment completion.
- Cash, equivalents & short-term investments: $151.9M at Dec 31, 2022, down from $225.5M; runway through end 2024.
- Q4 2022 net loss $3.7M vs net income $42.6M in Q4 2021; full-year net loss $12.0M vs $26.5M in 2021.

## SEC filing metadata
- accession: 0001818382-23-000014
- form_type: 8-K
- ticker: HUMA
- cik: 0001818382
- company_name: Humacyte, Inc.
- filed_at: 2023-03-24T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818382/000181838223000014/0001818382-23-000014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818382/000181838223000014/huma-20230324.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001818382-23-000014
- JSON: https://secwatch.observer/filing/0001818382-23-000014.json
- Plain text: https://secwatch.observer/filing/0001818382-23-000014.txt

## Key facts
- Earnings Releases
  Humacyte, Inc. reported financial results for fiscal fourth quarter and full year ended December 31, 2022.
  - Period: fiscal fourth quarter and full year ended December 31, 2022
  - Result: reported results
  source text: On March 24, 2023, Humacyte, Inc. issued a press release regarding its financial results for its fiscal fourth quarter and full year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818382/000181838223000014/0001818382-23-000014-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.